In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Congenital infection with human cytomegalovirus is a major cause of morbidity and mortality. A randomized controlled trial showed that high-dosage valacyclovir prevents cytomegalovirus disease in transplant recipients. Fetuses showing ultrasound features of infection are at high risk of being symptomatic at or before birth. In a pilot study, oral administration of high-dosage valacyclovir to mothers significantly decreased viral load and produced therapeutic concentrations in the blood of infected fetuses. A randomized controlled trial comparing prenatal treatment with valacyclovir against placebo in infected fetuses failed to recruit because women declined randomization. Randomized controlled trials in fetal medicine have often proven unacceptable by women who decline termination of pregnancy and are not prepared to resign themselves to the odds of the natural history of the disease. OBJECTIVE: We evaluated the efficacy of oral valacyclovir, 8 g daily, for pregnant women carrying a symptomatic cytomegalovirus-infected fetus, targeting a high-risk group for developing both neurosensory and neurological impairment. STUDY DESIGN: We designed a multicenter, open-label, phase II study with 1 arm, using one of Simon's optimal 2-stage designs. Symptomatic fetuses were defined by the presence of measurable extracerebral or mild cerebral ultrasound symptoms. They were treated in utero from prenatal diagnosis at a median of 25.9 weeks' gestation until delivery or termination of pregnancy. Fetuses with severe brain anomalies on ultrasound were not included as were cases completely asymptomatic at presentation, because treatment was unlikely to modify either outcome. The primary endpoint was the proportion of asymptomatic neonates born to treated mothers. RESULTS: At the interim analysis, 8 of 11 women delivered an asymptomatic neonate (required: ≥7). In step 2, 32 additional cases were included for a total of 43; the final number of asymptomatic neonates was 34, more than the 31 required to indicate efficacy according to the Simon 2-stage design. They remained asymptomatic at 12 months. High-dosage valacyclovir given for a median of 89 days to pregnant women carrying a moderately infected fetus was efficient at giving birth to asymptomatic neonates. Fetal blood viral loads decreased and platelet counts increased, both significantly (P = .01 and P < .001, respectively), between treatment initiation and birth after treatment completion, regardless of duration of fetal infection. Compared with a historical cohort obtained by a metaanalysis of the literature, the use of valacyclovir (8 g daily) significantly increased the proportion of asymptomatic neonates from 43% without treatment to 82% with treatment. Although the pill burden was high (16 pills a day) adherence to treatment was >90%. Finally, valacyclovir at this high dosage was extremely well tolerated. CONCLUSION: Our results indicate that high-dosage valacyclovir given in pregnancy is effective for improving the outcome of moderately symptomatic infected fetuses. Although this study is not a randomized controlled trial, this is the first study reporting the efficacy of an antiviral drug to treat cytomegalovirus-infected fetuses. Moreover, this first study will allow new trials to be conducted, using valacyclovir as a baseline safe and effective treatment in pregnancy, to be compared to the new emerging and more potent anticytomegalovirus drugs that have not currently been tested in pregnancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Estimation of fetal weight with the use of head, body, and femur measurements—A prospective study
Hadlock, F. P., Harrist, R. B., Sharman, R. S., Deter, R. L., & Park, S. K. (1985) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(85)90298-4 · Cited by 2,682
Review and meta‐analysis of the epidemiology of congenital cytomegalovirus (CMV) infection
Kenneson, A., & Cannon, M. J. (2007) · Reviews in Medical Virology · doi:10.1002/rmv.535 · Cited by 1,720 · cited 1×
“7% of live births and is the leading cause of congenital neurological disease of infectious origin.(1) Among all neonates positive for infection on screening, 20% eventually have neurodevelopmental impairment with permanent sequelae.”
BackgroundDollard, S. C., Grosse, S. D., & Ross, D. S. (2007) · Reviews in Medical Virology · doi:10.1002/rmv.544 · Cited by 1,257 · cited 2×
“Among all neonates positive for infection on screening, 20% eventually have neurodevelopmental impairment with permanent sequelae.(2) Around 10% of infected neonates are symptomatic at birth; their risk of sequelae reaches 58%, including sensorineural hearing loss or cognitive or motor defects.”
BackgroundValganciclovir for Symptomatic Congenital Cytomegalovirus Disease
Kimberlin, D. W., Jester, P. M., Sánchez, P. J., Ahmed, A., Arav-Boger, R., Michaels, M. G., Ashouri, N., Englund, J. A., Estrada, B., Jacobs, R. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1404599 · Cited by 827
Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection
Nigro, G., Adler, S. P., La Torre, R., & Best, A. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043337 · Cited by 784
Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation
Lowance, D., Neumayer, H.-H., Legendre, C. M., Squifflet, J.-P., Kovarik, J., Brennan, P. J., Norman, D., Mendez, R., Keating, M. R., Coggon, G. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401903 · Cited by 712 · cited 2×
“Although valacyclovir is less effective than ganciclovir against CMV in vitro,(15) high-dosage valacyclovir has proven clinically efficient to prevent CMV disease in transplant recipients.(16) The mechanism of acyclovir’s anti-CMV activity in clinical settings remains unexplained.”
BackgroundRelton, C., Torgerson, D., O'Cathain, A., & Nicholl, J. (2010) · BMJ · doi:10.1136/bmj.c1066 · Cited by 518
A Randomized Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus
Revello, M. G., Lazzarotto, T., Guerra, B., Spinillo, A., Ferrazzi, E., Kustermann, A., Guaschino, S., Vergani, P., Todros, T., Frusca, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310214 · Cited by 489 · cited 1×
“The use of CMV-specific hyperimmune globulin to prevent transmission from mother to fetus has produced conflicting results.(12,13) Neonatal antiviral treatment with either ganciclovir or valganciclovir improves auditory and neurological outcomes in symptomatic newborns,(14) but these drugs, highly genotoxic in vitro,…”
BackgroundLIESNARD, C. (2000) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(99)00657-2 · Cited by 270
A series of 238 cytomegalovirus primary infections during pregnancy: description and outcome
Picone, O., Vauloup‐Fellous, C., Cordier, A. G., Guitton, S., Senat, M. V., Fuchs, F., Ayoubi, J. M., Grangeot Keros, L., & Benachi, A. (2013) · Prenatal Diagnosis · doi:10.1002/pd.4118 · Cited by 262 · cited 1×
“Women carrying an infected fetus that appeared completely asymptomatic on ultrasound and had normal laboratory results were similarly excluded, because their outcome is known to be generally good.(4,9,29,30) In a previous study, we showed that odds ratio for a poor outcome was 4.”
BackgroundSelf-citationUltrasound prediction of symptomatic congenital cytomegalovirus infection
Guerra, B., Simonazzi, G., Puccetti, C., Lanari, M., Farina, A., Lazzarotto, T., & Rizzo, N. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.09.052 · Cited by 253 · cited 1×
“e3 American Journal of Obstetrics & Gynecol articles, but only 3 were written in English and included detailed tables that described both prenatal ultrasound findings and neonatal outcome and also included postmortem findings in termination of pregnancy cases.(10,24,25) These 3 suitable studies included 724 pregnancie…”
BackgroundMaternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection
Jacquemard, F., Yamamoto, M., Costa, J., Romand, S., Jaqz‐Aigrain, E., Dejean, A., Daffos, F., & Ville, Y. (2007) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2007.01308.x · Cited by 245 · cited 4×
“OCTOBER 2016 Ameri study conducted from 2003 through 2005 that suggested treatment with highdosage valacyclovir given orally to pregnant women carrying a symptomatic fetus infected with CMV could decrease viral DNA loads and achieve therapeutic concentrations in fetal blood.(10) A phase II randomized placebo-controlle…”
BackgroundSelf-citationPasternak, B. (2010) · JAMA · doi:10.1001/jama.2010.1206 · Cited by 230
Diagnosis and antenatal management of congenital cytomegalovirus infection
Hughes, B. L., & Gyamfi-Bannerman, C. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2016.02.042 · Cited by 203
Stone, K. M., Reiff‐Eldridge, R., White, A. D., Cordero, J. F., Brown, Z., Alexander, E. R., & Andrews, E. B. (2004) · Birth Defects Research Part A: Clinical and Molecular Teratology · doi:10.1002/bdra.20013 · Cited by 196 · cited 1×
“Neither cell transformation nor increased risk of neoplasia has been reported in vitro, and no increased risk of birth defects has been detected in the offspring of thousands of women exposed during pregnancy.(17,18) Finally, valacyclovir is well tolerated with rare side effects.”
BackgroundPrenatal diagnosis of symptomatic congenital cytomegalovirus infection
Guerra, B., Lazzarotto, T., Quarta, S., Lanari, M., Bovicelli, L., Nicolosi, A., & Landini, M. P. (2000) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2000.106347 · Cited by 189
Picone, O., Simon, I., Benachi, A., Brunelle, F., & Sonigo, P. (2008) · Prenatal Diagnosis · doi:10.1002/pd.2037 · Cited by 164 · cited 1×
“e3 American Journal of Obstetrics & Gynecol articles, but only 3 were written in English and included detailed tables that described both prenatal ultrasound findings and neonatal outcome and also included postmortem findings in termination of pregnancy cases.(10,24,25) These 3 suitable studies included 724 pregnancie…”
BackgroundSelf-citationBenoist, G., Salomon, L. J., Mohlo, M., Suarez, B., Jacquemard, F., & Ville, Y. (2008) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.6129 · Cited by 164
Self-citationBenoist, G., Salomon, L. J., Jacquemard, F., Daffos, F., & Ville, Y. G. (2008) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2008.01714.x · Cited by 155 · cited 5×
“Fetal blood sampling by cordocentesis under ultrasound guidance was offered to all participants to evaluate fetal platelets and viral DNA load to help refine the fetal prognosis.(4) Cordocentesis was not, however, required for study eligibility, as this invasive procedure was not the standard of care in all participat…”
BackgroundMethodSelf-citationGriffiths, P. D. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70197-4 · Cited by 151
Congenital cytomegalovirus: association between dried blood spot viral load and hearing loss
Walter, S., Atkinson, C. E., Sharland, M., Rice, P., Raglan, E., Emery, V. C., & Griffiths, P. D. (2007) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/adc.2007.119230 · Cited by 137
Prognostic implications of fetal echogenic bowel
Slotnick, R. N., & Abuhamad, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90210-x · Cited by 135
On the estimation of the binomial probability in multistage clinical trials
Jung, S., & Kim, K. M. (2004) · Statistics in Medicine · doi:10.1002/sim.1653 · Cited by 107 · cited 2×
“Proportion of asymptomatic neonates and 95% confidence interval (CI) were calculated with unbiased estimator.(26) In historical control group, we used random effects model to calculate overall proportion of asymptomatic neonates and 95% CI for 43 cases reported in 3 suitable published studies.”
MethodPrognostic markers of symptomatic congenital human cytomegalovirus infection in fetal blood
Fabbri, E., Revello, M. G., Furione, M., Zavattoni, M., Lilleri, D., Tassis, B., Quarenghi, A., Rustico, M., Nicolini, U., Ferrazzi, E. M., et al. (2010) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2010.02822.x · Cited by 106 · cited 3×
“Another observational study showed that a fetal platelet count <50,000/mm(3) had 80% predictive value for poor outcome.(6) We therefore enrolled women with either extracerebral or nonsevere cerebral ultrasound features, a low platelet count, or a high viral load in blood sampled in utero.”
BackgroundLipitz, S., Hoffmann, C., Feldman, B., Tepperberg-Dikawa, M., Schiff, E., & Weisz, B. (2010) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.7657 · Cited by 103
Leruez‐Ville, M., Sellier, Y., Salomon, L. J., Stirnemann, J., Jacquemard, F., & Ville, Y. G. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit059 · Cited by 102 · cited 1×
“ogy OCTOBER 2016 diagnosed by seroconversion or the concomitant presence of CMV-specific IgM antibodies and low IgG avidity.(22) After extracting DNA from fetal whole blood, cord whole blood, and neonatal urine with the MagnaPure LC platform (Roche Diagnostic, Meylan, France), we performed quantitative polymerase chai…”
MethodSelf-citationGuerra, B., Simonazzi, G., Banfi, A., Lazzarotto, T., Farina, A., Lanari, M., & Rizzo, N. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.08.039 · Cited by 99
Fetal liver ultrasound measurements during normal pregnancy.
Vintzileos, A. M., Neckles, S., Campbell, W. A., Andreoli, J., Kaplan, B., & NOCHIMSON, D. J. (1985) · PubMed · Cited by 81
Farkas, N., Hoffmann, C., Ben‐Sira, L., Lev, D., Schweiger, A., Kidron, D., Lerman‐Sagie, T., & Malinger, G. (2011) · Prenatal Diagnosis · doi:10.1002/pd.2694 · Cited by 78 · cited 1×
“Women carrying an infected fetus that appeared completely asymptomatic on ultrasound and had normal laboratory results were similarly excluded, because their outcome is known to be generally good.(4,9,29,30) In a previous study, we showed that odds ratio for a poor outcome was 4.”
BackgroundThe in vitro activity of Acyclovir and related compounds against cytomegalovirus infections
Tyms, A. S., Scamans, E., & Naim, H. M. (1981) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/8.1.65 · Cited by 69
Griffiths, P. D., Feinberg, J., Fry, J., Sabin, C. A., Dix, L. P., Gor, D., Ansari, A., & Emery, V. C. (1998) · The Journal of Infectious Diseases · doi:10.1086/513806 · Cited by 42 · cited 2×
“In renal transplantation and in HIV infection, high-dose regimens of valacyclovir are effective in preventing CMV disease and suppressing CMV viremia.(16,34,35) A sort of placebo effect may have also participated in the effect of valacyclovir.”
BackgroundUltrasound Examination of the Placenta
Grannum, P. A. T. (1983) · Clinics in Obstetrics and Gynaecology · doi:10.1016/s0306-3356(21)00585-9 · Cited by 18
Cited by
Rawlinson, W. D., Boppana, S. B., Fowler, K. B., Kimberlin, D. W., Lazzarotto, T., Alain, S., Daly, K., Doutré, S., Gibson, L., Giles, M. L., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30143-3 · Cited by 841
Chatzakis, C., Ville, Y., Makrydimas, G., Dinas, K., Zavlanos, A., & Sotiriadis, A. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.05.038 · Cited by 229
Self-citation
Metadata
- Authors
- Leruez-Ville, M., Ghout, I., Bussières, L., Stirnemann, J., Magny, J.-F., Couderc, S., Salomon, L. J., Guilleminot, T., Aegerter, P., Benoist, G., Winer, N., Picone, O., Jacquemard, F., & Ville, Y.
- Venue
- American Journal of Obstetrics and Gynecology
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 215
- Issue
- 4
- Pages
- 462.e1-462.e10
- ISSN
- 0002-9378 (ISSN-L)
- OpenAlex
- W2341411355
- Cited by
- 239
- References
- 33
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.